share_log

Panbela Therapeutics | CORRESP: CORRESP

SEC announcement ·  Jan 23 00:43
Summary by Futu AI
Panbela Therapeutics, Inc. has submitted a response to the U.S. Securities and Exchange Commission (SEC) regarding comments on its Registration Statement on Form S-1, initially filed on January 4, 2024. The correspondence, dated January 22, 2024, addresses the SEC's feedback from a letter dated January 9, 2024, and includes an Amendment No. 1 to the Registration Statement. The SEC had requested revisions to the cover page of the prospectus to specify the volume of Class E, Class F, and Pre-Funded Warrants being registered, as well as to disclose the termination date of the offering. Panbela Therapeutics has made the necessary revisions, including the quantities of the warrants and the specific offering termination date. The company has engaged Roth Capital Partners as its placement agent for the offering, which is being conducted on a best efforts basis. The response to the SEC was reviewed and approved by Panbela Therapeutics and includes input from the company's CEO, Jennifer K. Simpson, CFO Susan Horvath, and legal counsel from Faegre Drinker Biddle & Reath LLP.
Panbela Therapeutics, Inc. has submitted a response to the U.S. Securities and Exchange Commission (SEC) regarding comments on its Registration Statement on Form S-1, initially filed on January 4, 2024. The correspondence, dated January 22, 2024, addresses the SEC's feedback from a letter dated January 9, 2024, and includes an Amendment No. 1 to the Registration Statement. The SEC had requested revisions to the cover page of the prospectus to specify the volume of Class E, Class F, and Pre-Funded Warrants being registered, as well as to disclose the termination date of the offering. Panbela Therapeutics has made the necessary revisions, including the quantities of the warrants and the specific offering termination date. The company has engaged Roth Capital Partners as its placement agent for the offering, which is being conducted on a best efforts basis. The response to the SEC was reviewed and approved by Panbela Therapeutics and includes input from the company's CEO, Jennifer K. Simpson, CFO Susan Horvath, and legal counsel from Faegre Drinker Biddle & Reath LLP.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.